As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Insiya Klapper, who lives in the Capital Region, has experienced a transformative year, shedding 60 pounds with the help of ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

from sleep apnea to heavy drinking. The drugs became so popular so fast that manufacturers began running out, and patients ...

Related FDA approves weight-loss drug Zepbound to treat sleep apnea FDA says shortage of GLP-1 drug tirzepatide is over Merck reaches weight-loss drug deal worth up to $2 billion with China-based ...

Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...

Recent research suggests these drugs could help treat a variety of other conditions, from sleep apnea to heavy drinking ... and Monjauro or Zepbound (tirzepatide). There were other barriers ...

Zepbound is typically used to treat obesity–but it can also be used to help treat sleep apnea. Dr. Adhinav Singh joined FOX59 Morning News to discuss the treatment and why it may be ...